Tazeen Ahmad
BofA Securities, Research Division

Good afternoon or still good morning, I think. Welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior biotech analysts at the bank. It's my pleasure to have our next presenting company with us, Annexon Biosciences. Presenting for Annexon this morning will be Doug Love, who is President and CEO. Doug, welcome back to Las Vegas.

Douglas Love
CEO, President & Director

Thanks so much, Tazeen. We're always happy to be here. We appreciate Bank of America.

Tazeen Ahmad
BofA Securities, Research Division

So maybe we can just do a quick overview of Annexon, your platform and your programs, and then we can go into a little bit more detail on some of the upcoming data catalysts.

Douglas Love
CEO, President & Director

Yes, happy to do that. I'll be brief. Annexon is a leading neuroimmunology company -- it has been already. Anyway, we're targeting complement, which many of you are familiar with, a very differentiated approach. So we're targeting the classical complement pathway. And importantly, C1q, the initiator of the pathway, it's completely different from any other complement approach people may be familiar with in that C1q localizes and binds to disease tissue and a host of neuroinflammatory diseases in the body, brain and eye. We're 11 years into the journey, and we're more excited than ever at where we are. So after 11 years, we are led by 2 leading programs, one is in Guillain-Barre syndrome, an acute neuromuscular disease.

In fact, the leading cause of acute neuromuscular paralysis